Silexion Therapeutics completes key study on SIL-204 in pancreatic cancer models, initial results expected soon

Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA interference therapy, has reached a major milestone with the completion of its initial study evaluating SIL-204 in pancreatic cancer models. This marks the first systemic administration study of SIL-204 in clinically relevant orthotopic models, offering a more accurate representation of how the tre